Related Experiment Video
Updated: May 22, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies
Sai Kumar Madhavaram1, Samyuktha Srinivas2, Sarah A Bhanushali3
1Medicine, Manipal Academy of Higher Education, Manipal, IND.
None:
IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally, exhibiting marked diversity in clinical presentation, risk of progression, and response to therapy. Despite advances in understanding its pathophysiology, including the pivotal role of galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1 autoantibodies, and dysregulated mucosal and systemic immune responses, therapeutic options remain limited. This review provides a comprehensive overview of the current therapeutic landscape in IgAN, which is stratified into conservative care with renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and corticosteroids, and newer advances like the endothelin receptor antagonists, immunosuppressive agents, and targeted therapeutics. Through synthesizing evidence from recent clinical trials and ongoing studies, we aim to provide clinicians and researchers with a current and forward-looking perspective on therapeutic strategies in IgAN, emphasizing the shift from conservative therapy to targeted, individualized interventions.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Nephrotic Syndrome III : Nursing Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Nephrotic Syndrome I : Introduction
